Obesity on decline in US as GLP-1 use skyrockets: Gallup
The obesity rate in the U.S. has seen a marked decline over the last three years, as the share of Americans who report using GLP-1 agonists for weight loss skyrockets, according to data from Gallup. In the latest report from the Gallup National Health and Well-Being Index, published Tuesday, 37 percent of American adults are…
Cardioprotective Effects of Semaglutide Independent of Adiposity
WEDNESDAY, Oct. 29, 2025 — The cardioprotective effects of semaglutide are independent of baseline adiposity and weight loss, according to a study published online Oct. 22 in The Lancet.
John Deanfield, M.B., B.Chir., from University College…
What’s the Driving Force Behind Eli Lilly’s Recent Acquisition Spree?
Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive long-term growth. Although the cardiometabolic health space remains its core area, the company is also expanding strategically across various other therapeutic areas, like oncology, neuroscience and ophthalmology, through targeted deals. Last week, Lilly […]
The Hidden Toll of GLP-1 Care Complexity on PCPs
An obesity medicine specialist’s thoughts on reducing the burden of prior authorization, documentation, and follow-ups. Medscape Medical News
STAT+: Pharmalittle: We’re reading about Bausch exiting Medicaid, Lilly and NVIDIA’s supercomputer, and more
Rise and shine, everyone, another busy day is on the way. And given that this is the middle of the week, it may be a challenging one, too. But there is always the bright side to consider — the end of the week is now that much closer. Besides, the alternatives to being busy are […]
AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists
De novo GLP-1RAs can be computationally designed to exhibit extended half-life and superior efficacy compared to Semaglutide. Abstract Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and discovery. Here, an efficient approach that integrates deep learning-based […]
Weight-loss drugs are reshaping Whole Foods, one aisle at a time
Some seven million Americans are now on GLP-1 weight loss drugs, a figure expected to rise to 24 million by 2035. These medications curb users’ appetites for fatty, ultra-processed foods, and grocery stores are noticing: total sold units of doughnuts, cakes, and cookies are down by 10%, 19%, and 13%, respectively, compared to five years […]
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
Key Points BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs. However, BioAge is an early-stage biotech whose prospects still look incredibly risky. 10 stocks we like better than BioAge Labs › Biotech investors have been closely monitoring the weight management space over the past […]
Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials
Abstract Aims To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose transport protein-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD). Materials and Methods PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched through July 2025 for randomized controlled trials […]
Effectiveness and safety of GLP‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
Abstract Aims Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real-world effectiveness and safety of GLP-1 RAs in this population. Materials and Methods CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP-1 RAs across […]